AC Immune
at AD/PD
™ 202
3
to
Present
New Clinical and Preclinical Data f
rom
its Precision Medicine Pipeline
- Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)
- AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s disease
Lausanne, Switzerland,
March
20
,
202
3 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC Immune, will join an expert panel to discuss the latest developments in immunotherapies in Alzheimer’s disease.
Andrea Pfeifer,
Ph
.
D
.
,
CEO of AC Immune SA, commented: “The ten presentations during this AD/PDTM conference demonstrate AC Immune’s progress towards our over-arching goal, which is to shift the treatment paradigm towards Precision Medicine and disease prevention. As our clinical programs in Alzheimer’s and Parkinson’s diseases are advancing, we are solidifying our position as a leading developer of vaccines for neurodegenerative diseases. AC Immune’s cutting-edge therapeutic and diagnostic research programs pursuing multiple validated molecular targets, highlight the breadth of our pipeline. These will drive our differentiated Precision Medicine approach in neurodegeneration and become substantial value creating catalysts.”
AC Immune p
resentations
at
AD/PDTM
202
3
(all times are CE
S
T)
Roundtable discussion
Forum 02:
I
mmunotherapies in
AD
: from basics to approval
Date: Wed, 29.03.2023 | 03:55 PM – 04:55 PM | Hall C
Panelist: Forum discussion with Johannes Streffer, M.D., (AC Immune)
Active immunotherapy
A
BATE
study –
U
tilizing biomarker-based development for optimized
ACI
-24, a novel candidate vaccine for the treatment and prevention of
A
lzheimer’s
disease
Date: Sat, 01.04.2023 | 05:55 PM – 06:10 PM | Hall G3
Presenter: Oral presentation by Johannes Streffer, M.D., (AC Immune)
Beneficial effect of
ACI
-24 vaccination on
A
beta plaque pathology and microglial phenotypes in an amyloidosis mouse model
Date: Sat, 01.04.2023 | 09:25 AM – 09:40 AM | Hall G4
Presenter: Oral presentation by Sabina Tahirovic, Ph.D., (German Center for Neurodegenerative Diseases)
A novel anti-amyloid beta (
A
beta) vaccine, a potent immunotherapy for the prevention and treatment of
A
lzheimer’s disease in
D
own syndrome
Date: Sat., 01.04.2023 | 07:00 AM – 08:30 AM | OD349 / #1688
Presenter: On-demand symposium by Emma Fiorini, Ph.D. (AC Immune)
Vac
SY
n
study design – biomarker-based development for
ACI
-7104, a novel candidate vaccine for the treatment and prevention of
P
arkinson’s disease
Date: Available online from Tue, 28.03.2023 | Poster P0313 / #1791
Presenter: On demand presentation by Dymitr Kostrica, Ph.D. (AC Immune)
Passive
immunotherapy
Antibody-mediated inhibition of
ASC
attenuates inflammasome activation in vitro and in a mouse model of
demyelination
Date: Wed, 29.03.2023 | 04:15 PM – 04:30 PM | Hall G4
Presenter: Oral presentation by Davide Basco, Ph.D. (AC Immune)
Development of
TDP
-43 immunotherapy blocking transmission of seeding-competent species from
ALS/FTD
Date: Thu, 30.03.2023 | 06:05 PM – 06:20 PM | Hall G3
Presenter: Oral presentation by Tariq Afroz, Ph.D. (AC Immune)
Small molecules
Discovery of therapeutic small molecules targeting alpha-synuclein aggregation
Date: Fri, 31.03.2023 | 07:00 AM – 08:30 AM | OD209 / #1442
Presenter: On demand presentation by Elpida Tsika, Ph.D. (AC Immune)
Diagnostics & biomarkers
Discovery and in
i
tial clinical evaluation
[18
F
]
ACI
-12589, a novel and promising
PET
-tracer for a-synuclein
Date: Thu, 30.03.2023 | 09:40 AM – 09:55 AM | Hall F4+F5
Presenter: Oral presentation by Francesca Capotosti, Ph.D. (AC Immune)
Compartmentalization of plasma
TDP
-43 in platelets: implications for
TDP
-43-related biomarker development
Date: Thu, 30.03.2023 | 02:05 PM – 02:20 PM | Hall G3
Presenter: Oral presentation by Ruth Luthi-Carter, Ph.D. (AC Immune)
Optimization of affinity, selectivity and pharmacokinetic profile of
TDP
-43
PET
ligands
Date: Available online from Tue, 28.03.2023 | Poster P0994 / #979
Presenter: On demand presentation by Tamara Seredenina, Ph.D. (AC Immune)
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
|
Head of Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: [email protected] |
U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: [email protected] |
|
International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: [email protected] |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
